Moleculin Biotech (NASDAQ:MBRX) Upgraded to Sell at Wall Street Zen

Posted by Francis Steltz on Aug 16th, 2026

Wall Street Zen upgraded shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) from a strong sell rating to a sell rating in a research report sent to investors on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $22.00.

Get Our Latest Research Report on Moleculin Biotech

Moleculin Biotech Stock Up 6.8%

Shares of Moleculin Biotech stock opened at $0.61 on Friday. Moleculin Biotech has a 52 week low of $0.16 and a 52 week high of $17.23. The firm’s 50 day moving average is $2.03 and its two-hundred day moving average is $2.50. The firm has a market capitalization of $4.33 million, a P/E ratio of -0.03 and a beta of 1.83.

Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($1.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.55) by $0.15. As a group, research analysts expect that Moleculin Biotech will post -3.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Moleculin Biotech

A hedge fund recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech at the end of the most recent quarter. Institutional investors own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

(Get Free Report)

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.